OlympiAD扩展随访的总生存与安全性:奥拉帕利对比医生选择化疗用于胚系BRCA突变且HER2阴性转移性乳腺癌患者
OlympiAD III期研究扩展随访显示,在胚系BRCA突变且HER2阴性转移性乳腺癌患者中,奥拉帕利组中位总生存19.3个月,医生选择化疗组17.1个月(HR 0.89,95%CI 0.67-1.18),与既往分析一致;一线转移治疗亚组中奥拉帕利组中位总生存22.6个月,化疗组14.7个月(HR 0.55,95%CI 0.33-0.95)。未观察到奥拉帕利相关的新严重不良事件。
要点
- 总体人群奥拉帕利组中位总生存19.3个月 vs 化疗组17.1个月,HR 0.89(95%CI 0.67-1.18)。
- 一线转移治疗亚组奥拉帕利组中位总生存22.6个月 vs 化疗组14.7个月,HR 0.55(95%CI 0.33-0.95)。
- 奥拉帕利组8.8%患者接受研究治疗≥3年,化疗组无患者接受≥3年。
核心结论
- 总生存结果与OlympiAD既往分析一致,支持奥拉帕利可能带来有意义的长期生存获益,尤其是一线转移性乳腺癌。
研究设计与样本
- III期OlympiAD研究扩展随访,患者为胚系BRCA突变且HER2阴性转移性乳腺癌、转移阶段接受≤2线化疗,按2:1随机分配至奥拉帕利300 mg每日两次或医生选择化疗。
- 扩展随访期间每6个月分析总生存,总体人群采用分层log-rank检验,预设亚组采用Cox比例风险模型。
- 总体人群302例患者,总生存数据成熟度76.8%。
主要发现
- 总体人群中位总生存奥拉帕利组19.3个月 vs 医生选择化疗组17.1个月(HR 0.89,95%CI 0.67-1.18);中位随访分别为18.9个月和15.5个月。
- 三年生存率奥拉帕利组27.9% vs 医生选择化疗组21.2%。
- 奥拉帕利组8.8%患者接受研究治疗≥3年,医生选择化疗组无患者接受≥3年。
- 一线转移性乳腺癌亚组中位总生存奥拉帕利组22.6个月 vs 医生选择化疗组14.7个月(HR 0.55,95%CI 0.33-0.95);三年生存率奥拉帕利组40.8% vs 医生选择化疗组12.8%。
- 未观察到奥拉帕利相关的新严重不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the Phase III OlympiAD study, olaparib significantly prolonged progression-free survival versus chemotherapy treatment of physician's choice (TPC) in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2-negative metastatic breast cancer (mBC). In the final pre-specified analysis (64% maturity), median overall survival (OS) was 19.3 months for olaparib and 17.1 months for TPC (P = 0.513). Post-hoc extended follow-up, 25.7 months longer than previously reported for OS, is reported. PATIENTS AND METHODS: Patients with gBRCAm, human epidermal growth factor receptor 2-negative mBC, who had received ≤2 lines of chemotherapy for metastatic disease, were randomised 2:1 to olaparib (300 mg bid) or TPC. During extended follow-up, OS was analysed every 6 months using the stratified log-rank test (overall population) and Cox proportional hazards model (pre-specified subgroups). RESULTS: In the overall population (302 patients; 76.8% maturity), median OS was 19.3 months for olaparib and 17.1 months for TPC (hazard ratio 0.89, 95% confidence interval 0.67-1.18); median follow-up was 18.9 and 15.5 months, respectively. Three-year survival was 27.9% for olaparib versus 21.2% for TPC. With olaparib, 8.8% of patients received study treatment for ≥3 years versus none with TPC. In first-line mBC, median OS was longer for olaparib than TPC (22.6 versus 14.7 months; hazard ratio 0.55, 95% confidence interval 0.33-0.95) and 3-year survival was 40.8% for olaparib versus 12.8% for TPC. No new serious adverse events related to olaparib were observed. CONCLUSIONS: OS was consistent with previous analyses from OlympiAD. These findings support the possibility of meaningful long-term survival benefit with olaparib, particularly in first-line mBC.
引用
- Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023. PMID: 36893711. doi:10.1016/j.ejca.2023.01.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。